ArticleRMD open2026
Risk of cognitive disorders in patients with primary Sjögren's disease: data from Korean Health Insurance Service.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the risk of incident cognitive disorders in patients with primary Sjögren's disease (pSjD) using nationwide Korean National Health Insurance Service data.
methodsThis retrospective cohort study included patients newly diagnosed with pSjD between 2010 and 2021 and propensity score-matched controls. The primary outcome was a composite of Alzheimer's dementia (AD), vascular dementia (VaD), secondary dementia, unclassified dementia and mild cognitive impairment (MCI). Adjusted HRs (aHRs) and 95% CIs were estimated using multivariable Cox regression. Age-stratified analyses were also performed.
resultsA total of 12 731 patients with pSjD and 36 514 matched controls were analysed. pSjD was associated with increased risks of total cognitive disorders (aHR 1.48, 95% CI 1.36 to 1.63), AD (aHR 1.48, 95% CI 1.35 to 1.63), secondary dementia (aHR 2.24, 95% CI 1.45 to 3.48), unclassified dementia (aHR 1.43, 95% CI 1.21 to 1.70) and MCI (aHR 1.62, 95% CI 1.41 to 1.85). In age-stratified analyses, pSjD was associated with an increased risk of MCI among participants aged <65 years (aHR 1.46, 95% CI 1.06 to 2.01). Among those aged 65-74 years, pSjD was associated with increased risks of total cognitive disorders, AD and MCI.
conclusionspSjD was associated with increased risks of multiple cognitive disorders. The age-specific patterns-an increased risk of MCI among individuals aged <65 years and increased risks of total cognitive disorders, AD and MCI among those aged 65-74 years-underscore the need for clinical attention to cognitive symptoms across age groups in patients with pSjD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.